medigraphic.com
Colegio de Medicina Interna de México.

2010, Número 2

<< Anterior Siguiente >>

Med Int Mex 2010; 26 (2)


Prevalencia de alteraciones cognitivas en pacientes con VIH/SIDA en una cohorte mexicana

Galindo SJ, Rodríguez AJV, Sandoval RJL, Tejada GRA

Idioma: Español
Referencias bibliográficas: 53
Paginas: 116-122
Archivo PDF: 316.41 Kb.


RESUMEN

Antecedentes: las alteraciones cognitivas asociadas con el VIH provocan déficit adquirido de habilidades cognitivas combinadas que pueden incluir: función motora, comportamiento y cognición, lo que contribuye al aumento de la morbilidad de la infección por VIH y es un importante factor de riesgo de mortalidad.
Material y método: encuesta prospectiva realizada en el Hospital General de Zona número 11 del Instituto Mexicano del Seguro Social con la población de pacientes que acuden a la consulta externa de infectología con el diagnóstico de VIH/SIDA. Se utilizó el Mini Mental State Exam (MMSE) para identificar las alteraciones neurológicas encontradas en esta cohorte.
Resultados: se entrevistaron 119 pacientes, de los que 91 fueron de género masculino y 28 del femenino. La edad promedio en años al momento del estudio fue de 39.21 ± 10.3 y el tiempo de tratamiento en meses de 63.63 ± 38.89. El 66% de los pacientes encuestados tenia una capacidad cognitiva normal, en 22% había una sospecha de afectación y 11% cursaba con deterioro cognitivo. No se reportó caso alguno de demencia.
Conclusiones: con base en el MMSE 66% de nuestra población tiene capacidad cognitiva normal, el resto cursa con sospecha de afectación o deterioro cognitivo comprobado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. McArthur JC, Hoover DR, Bacellar H, et al. Multicenter AIDS Cohort Study. Dementia in AIDS patients: incidence and risk factors. Neurology 1993;43:2245-2252.

  2. Justice AC, McGinnis KA, Atkinson JH, et al. Psychiatric and neurocognitive disorders among HIV – positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS 2004;18 (suppl 1):S49-S59.

  3. Cliford BD. AIDS dementia. Med Clin N Am 2002;86:537- 550.

  4. Antinori A, Arendt G, Becker JT. Updated research nosology for HIV associated neurocognitive disorders. Neurology 2007;69:1789-1799.

  5. An SF, Giometto M, Miller RF, et al. Axonal damage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS. J Neuropathol Exp Neurol 1997;56:1262-1268.

  6. Lipton SA, Gendelman HE. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995;332:934- 940.

  7. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136-142.

  8. Bacellar H, Muñoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1–related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994;44:1892- 1900.

  9. Goodwin GM, Pretsell DO, Chiswick A, et al. The Edinburgh cohort of HIV-positive injecting drug users at 10 years after infection: a case control study of the evolution of dementia. AIDS 1996;10:431-440.

  10. Chiesi A, Vella S, Dally LG, et al. Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:39-44.

  11. Brew BJ, Dunbar N, Pemberton L, Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of _2-microglobulin and neopterin. J Infect Dis 1996;174:294-298.

  12. Bouwman FH, Skolasky RL, Hes D, et al. Variable progression of HIV-associated dementia. Neurology 1998;50:1814-1820.

  13. Qureshi AI, Hanson DL, Jones JL, Janssen RS. Estimation of the temporal probability of human immunodeficiency virus (HIV) dementia after risk stratification for HIV-infected persons. Neurology 1998;50:392-397.

  14. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999;52:607-613.

  15. D’Arminio MA, Duca PG, Vago L, Grassi MP, Moroni M. Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy. Neurology 2000;54:1856- 1859.

  16. Stern Y, McDermott MP, Albert S, et al. Factors associated with incident human immunodeficiency virus dementia. Arch Neurol 2001;58:473-479.

  17. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 1992;42:1472-1476.

  18. Wang F, So Y, Vittinghoff E, et al. Incidence proportion of and risk factors for AIDS patients diagnosed with HIV dementia, central nervous system toxoplasmosis, and cryptococcal meningitis. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:75-82.

  19. Goodkin K, Wilkie FL, Concha M, et al. Aging and neuro-AIDS conditions and the changing spectrum of HIV-1- associated morbidity and mortality. J Clin Epidemiol 2001;54 (Suppl. 1): S35-S43.

  20. Bell JE, Donaldson YK, Lowrie S, et al. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS 1996;10:493- 499.

  21. Wilkie FL, Goodkin K, Eisdorfer C, et al. Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatry Clin Neurosci 1998;10:125-132.

  22. Beach RS, Morgan R, Wilkie F, et al. Plasma vitamin B12 level as a potential cofactor in studies of human immunodeficiency virus type 1–related cognitive changes. Arch Neurol 1992;49:501-506.

  23. Herzlich BC, Schiano TD. Reversal of apparent AIDS dementia complex following treatment with vitamin B12. J Intern Med 1993;233:495-497.

  24. Shor-Posner G, Morgan R, Wilkie F, Eisdorfer C, Baum MK. Plasma cobalamin levels affect information processing speed in a longitudinal study of HIV-1 disease. Arch Neurol 1995;52:195-198.

  25. Marder K, Sterh Y, Malouf R, et al. Neurologic and neuropsychological manifestations of human immunodeficiency virus infection in intravenous drug users without acquired immunodeficiency syndrome: relationship to head injury. Arch Neurol 1992;49:1169-1175.

  26. Poutiainen E. Cognitive deficits and emotional disorders in HIV-1 infected individuals. Acta Psychiatr Scand 1995;92:429- 435.

  27. Satz, Mongenstem H, Miller EN. Low education as possible risk factor for cognitive abnormalities in HIV-1: findings from the Multicenter AIDS Cohort Study (MACS). J Adquir Immune Defic Syndr 1993;6:503-511.

  28. Maj M, Satz P, Janssen R. WHO Neuropsychiatric AIDS Study, cross-sectional phase II: neuropsychological and neurological findings. Arch Gen Psychiatry 1994;51:51-61.

  29. Sterm RA, Silva SG, Chaisson N, Evans DL. Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infectio. Arch Neurol 1996;53:148-153.

  30. Starace F, Baldassare C, Biancolili V. Early neuropsychological impairment in HIV-seropositive intravenous drugs users: evidence from the Italian Multicentre Neuropsychological HIV Study. Acta Psychiatr Scand 1998;97:132-138.

  31. Grant I, Heaton RK, Atkinson JH, for the HIV Neurobehavioral Research Center Group. Neurocognitive disorders in HIV-1 infection. Curr Top Microbiol Immunol 1995;202:11- 32.

  32. McArthur JC, Sacktor N, Selnes O. Human immunodeficiency virus-associated dementia. Semin Neurol 1999;19:129-150.

  33. Grassi MP, Perin C, Clerici F, et al. Neuropsychological performance in HIV-1-infected drug abusers. Acta Neurol Scand 1993;88:119-122.

  34. McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003;9:205-221.

  35. Sacktor NC, Bacellar H, Hoover DR, et al. Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death. J Neurovirol 1996;2:404-410.

  36. Albert SM, Marder K, Dooneief G, et al. Neuropsychologic impairment in early HIV infection. A risk factor for work disability. Arch Neurol 1995;52:525-530.

  37. Price RW, Yiannoutsos CT, Clifford DB, et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS 1999;13:1677-1685

  38. Ammassari AA, Starace F, Aloisi MS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 2002;59:1944-1950.

  39. Power C, Selnes OA, Grim JA, McArthur JC. The HIV Dementia Scale: a rapid screening test. J AIDS 1995;8:273-278.

  40. Davis HF, Skolasky RL , Selnes OA, et al. Assessing HIVassociated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read 2002;12:29-31,38.

  41. Power C, Selnes OA, Grim JA, McArthur JC. The HIV Dementia Scale: a rapid screening test. J AIDS 1995;8:273-278.

  42. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005;19:1367-1374.

  43. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.

  44. Bleecker ML, Bolla-Wilson K, Kawas C, Agnew J. Agespecific norms for the Mini-mental State Exam. Neurology 1988;38:1565-1568.

  45. Lobo A, Ezquerra J, Gomez F, et al. El Mini-Examen Cognoscitivo (Un test sencillo, práctico, para la detección de alteraciones intelectuales). Actas Luso-Españolas Neurol Psiquiat 1979;7:189-202.

  46. Lobo A, Saz P, Marcos G, et al. Revalidación y normalización del mini-examen cognoscitivo (primera versión en castellano del MMSE) en población general geriátrica. Med Clin 1999;20:767-774.

  47. Quiroga P, Albala C, Klaasen G. Validación de un test de tamizaje para el diagnóstico de demencia asociada a edad, en Chile. Rev Méd Chile 2004;132:467-478.

  48. Velásquez-Monrroy O, Rosas PM, Lara E, Pastelín HG, grupo ENSA 2000. Hipertensión arterial en México: Resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2002;72:71-84.

  49. Deshpande AK, Patnaik MM. Non opportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study. Med Gen Med 2005;7:2.

  50. Dore GJ, Correll OK, Li Y, et al. Changes to AIDS dementia complex in the era of highly active antirretroviral therapy. AIDS 1999;13:1249-1253.

  51. Wong MH, Robertson K, Nakasujja N, et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 2007;68:350-355.

  52. Riedel D, Ghate M, Nene M, et al. Screening for human immunodeficiency virus (HIV) dementia in an HIV clade Cinfected population in India. J Neurovirol 2006;12:34-38.

  53. McMurtray A, Clark DG, Christine D, Mendez MF. Early-onset dementia: frequency and causes compared to late-onset dementia. Dement Geriatr Disord 2006;21:59-64.




2020     |     www.medigraphic.com